Thursday, September 03, 2015 11:19:46 AM
Here's the little blurb that Phaedrus77 pointed out from the 10K:
"
Cost of sales was $18,269,192 (82% of sales) and $18,107,627 (77% of sales) in fiscal years 2015 and 2014, respectively. The ratio of cost of pallet sales to pallet sales in fiscal year 2015 was 81% in fiscal year 2015 compared 75% for fiscal year 2014. The increase in cost of sales in fiscal year 2015 compared to 2014 is principally due to the inflexible fixed costs in pallet production and development costs incurred during the last three months of fiscal year 2015 in preparation to meet the production requirements for new customers.
"
I wanted to figure out how much was spent for these new customers:
-- pallet sales total for 2015 = 21,064,335, so at 81% the cost of pallet sales was 17,062,111.
-- pallet sales total for 2014 = 22,086,768, so at 75% the cost of pallet sales was 16,565,076
So in 2015 there was an extra 497,035 spent. That's a pretty good chunk of change. Since they reference "inflexible fixed costs" it seems that about this much was spent on preparing for the new customers.
====================================================================
www.nonamestocks.com
Recent GLGI News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 05:36:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 07:10:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 03:47:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:17:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 05:58:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/16/2023 08:30:31 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/28/2023 09:28:37 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2023 06:22:11 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM